Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 16/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.60 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607771 | 1.00 | HDAC4 (0.60) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608228 | 0.91 | HDAC1 (0.60) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608231 | 0.91 | HDAC1 (0.60) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608507 | 0.90 | HDAC6 (0.58) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608509 | 0.90 | HDAC6 (0.58) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608728 | 0.89 | HDAC6 (0.59) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608727 | 0.89 | HDAC6 (0.59) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608832 | 0.88 | HDAC4 (0.57) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608834 | 0.88 | HDAC4 (0.57) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL1608640 | 0.85 | HDAC8 (0.54) | HDAC4HDAC3HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265590-B1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | HDAC4 8/4885HDAC3 9/4885HDAC1 2/4885 |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | HDAC8, HDAC1, HDAC5 | HDAC4 10/4885HDAC3 9/4885HDAC1 2/4885 |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | HDAC4 8/4885HDAC3 9/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.